Guidelines on the benefit-risk assessment (BRA) of the presence, in the medical devices specified in the regulation, of phthalates which have one or more of the following properties: carcinogenic, mutagenic, toxic to reproduction (CMR) or endocrine-disrupting (ED), according to the criteria outlined in MDR Annex I section 10.4.2.